| zurück
Home |
RA, Rheumatoide Arthritis: Therapie |
| allgemeines |
| DMARD |
Disease modifying anti-rheumatic drugs |
- TNF-IH: Eternacept, Adalimumab
- IL6-R: Sarilumab, Tocilizumab
- CD20, B-Zelle: Rituximab
- CD80/86, T-Zelle: Abatacept
- IL12/23: Usdekinumab
- Phosphodiesterase: Apremilast
- JAK: Baricinib, Tofacitinib
|
| TNF-IH |
in Deutschland zugelassene
TNF-Inhibitoren
- Etanercept, Erelzi®, Enbrel®
- Certolizumab, Comzia®
- Adalimumab, Abbvie®
- Infliximab, Remicade®
- Golimumab, Simponi®
|
| Siltuximab, SYLVANT® |
IL6-IH |
SIR-ROUND-T-Studie(1): Besserung bei aktiver rheumatoider Arthritis trotz Anti-TNF-Vortherapie: |
| Janus - Kinase IH |
Tofacitinib |
JAK-IH |
| Upadacitinib |
JAK1-IH |
Phase III-Studie: SELECT-NEXT (2) |
| Abatacept |
Fusion von CTLA4 und IG-Fragment. |
Blockiert den CD80/86-Komplex der
Antigen-präsentierenden Zellen. |
Verhindert eine
T-Zell-Aktivierung. |
| Hydroxychloroquin |
Quensyl® 155mg FT |
Ursprünglich Malaria - Prophylaxe. Jetzt auch bei
entzündlichen Bindegewebserkrankungen (LE, rA) |
| Quelle |
1.) Aletaha D, Bingham III CO, Tanaka Y, et al.:
Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomized, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Lancet 2017; 398: 1206–17
2.) Burmester GR, Kremer JM, Van den Bosch F, et al.:
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs
(SELECT-NEXT): a randomised, double-blind, placebocontrolled phase 3 trial.
Lancet 2018; 391: 2503–12.
|
 |